Nicotine Gums and Mints Market

How big is the Nicotine Gums and Mints Market in 2026?

The Nicotine Gums and Mints Market is projected to reach USD 3,245 million by 2036, growing at a 5.5% CAGR from 2026 to 2036.

FMI estimates the market at USD 1,900 million in 2026. The market was valued at USD 1,800 million in 2025. Demand is tied to the number of smokers who try to quit. Pharmacies and drug stores lead distribution with 61.0% of 2026 revenue. Rules on over-the-counter access, particularly in India, are the main commercial risk. Quit attempts, not smoker counts, set the volume that nicotine gum can reach. India's 2016 to 2017 survey recorded 99.5 million smokers. Among smokers and recent quitters, 38.5% had tried to quit within a year. In the United States, 28.8 million adults smoked in 2022 and 53.3% of smokers and recent quitters tried to quit. Only 8.8% quit successfully that year. Substitutes narrow the usable pool in markets where vapes are legal. In England, over-the-counter nicotine replacement featured in 17.3% of quit attempts in 2023 to 2024, while vapes reached 40.2%.

Key Market Trends & Insights

• Brand ownership is changing. Kimberly-Clark completed its acquisition of Kenvue, owner of Nicorette, on 2 November 2026. Dr. Reddy's Laboratories had bought the Nicotinell portfolio outside the United States for an up-front GBP 458 million in 2024.
• Store brands are gaining share. Perrigo reported on 4 November 2026 that store brand nicotine replacement drove growth in its Healthy Lifestyle category.
• Digital support is being attached to gum. Cipla Health launched Nicotex Begin, a 12-week cessation app that combines behavioral therapy with nicotine replacement, in May 2025.

Regional Highlights

• In North America, store brands are gaining share in nicotine replacement. In the United States, 38.3% of adults who tried to quit used counseling or medication in 2022.
• In South Asia, regulation could decide growth. India's Drugs Technical Advisory Board recommended in February 2026 that over-the-counter sale cover only unflavoured 2 mg gum.

Nicotine Gums and Mints Market Size and Forecast

Table 1: Nicotine Gums and Mints Market Size and Forecast

Market size and forecast	Value
Market size in 2025	USD 1,800.0 million
Estimated market size in 2026	USD 1,900.0 million
Projected market size by 2036	USD 3,245.0 million
CAGR from 2026 to 2036	5.5%

Source: Future Market Insights analysis of the nicotine gums and mints market, 2026.

Analyst Perspective

“Nicotine gums and mints are regulated medicines in most countries, so growth depends on how easily smokers can buy them. Pharmacy shelf space, price against store brands and rules on flavors and strengths shape revenue. Brand ownership is changing in several markets, so supply terms will matter during integration. Falling smoking rates in mature markets shift growth toward Asia, where over-the-counter rules are still being set.”

- Nandini Roy Choudhury, Principal Consultant, FMI

How is the Nicotine Gums and Mints Market segmented?

• By product type: Nicotine gum, Nicotine mints and lozenges.
• By strength: Below 3 mg, 3 mg and above.
• By flavor: Mint, Fruit, Original and classic, Others.
• By distribution channel: Pharmacies and drug stores, Supermarkets and hypermarkets, Convenience stores, Online retail, Others.
• By region: North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa.

Why does Nicotine gum lead by Product Type in the Nicotine Gums and Mints Market in 2026?

Nicotine gum is estimated to account for 82.0% of the Nicotine Gums and Mints Market by product type in 2026.

Nicotine gum is one of five nicotine replacement medicines approved by FDA. Nicotine mints and lozenges account for the remaining 18.0%, and regulators set tighter conditions on lozenges in some markets. In India, the advisory board recommended excluding the 2 mg lozenge from the Schedule K exemption.

Table 2: Product Type, 2026 Share

Leading Share	2026 market share
Nicotine gum	82.0%
All Other Segments Combined Share	18.0%

Source: Future Market Insights analysis of the nicotine gums and mints market, 2026.

Why does Below 3 mg lead by Strength in the Nicotine Gums and Mints Market in 2026?

Below 3 mg strengths are estimated to account for 66.0% of the Nicotine Gums and Mints Market by strength in 2026.

Nicotine gum comes in 2 mg and 4 mg strengths. Smokers who have their first cigarette within 30 minutes of waking should consider starting with the 4 mg dose. India's recommended Schedule K amendment would keep only unflavoured 2 mg gum outside the sales-licence requirement. Strengths of 3 mg and above account for the remaining 34.0%.

Table 3: Strength, 2026 Share

Leading Share	2026 market share
Below 3 mg	66.0%
All Other Segments Combined Share	34.0%

Source: Future Market Insights analysis of the nicotine gums and mints market, 2026.

Why does Mint lead by Flavor in the Nicotine Gums and Mints Market in 2026?

Mint is estimated to account for 45.0% of the Nicotine Gums and Mints Market by flavor in 2026.

CDC lists mint, cinnamon and cherry among the available flavors of nicotine gum. Fruit, original and other flavors share the remaining 55.0%. India's recommended Schedule K amendment would leave only unflavoured gum outside the sales-licence requirement, which could narrow flavor choice there.

Table 4: Flavor, 2026 Share

Leading Share	2026 market share
Mint	45.0%
All Other Segments Combined Share	55.0%

Source: Future Market Insights analysis of the nicotine gums and mints market, 2026.

Why do Pharmacies and drug stores lead by Distribution Channel in the Nicotine Gums and Mints Market in 2026?

Pharmacies and drug stores are estimated to account for 61.0% of the Nicotine Gums and Mints Market by distribution channel in 2026.

In India, Cipla Health said in May 2025 that its products reach more than 600,000 of nearly 800,000 chemists. The board's February 2026 recommendation would limit the licence exemption to unflavoured 2 mg gum and exclude 2 mg lozenges. Supermarkets, convenience stores, online retail and other channels share the remaining 39.0%.

Table 5: Distribution Channel, 2026 Share

Leading Share	2026 market share
Pharmacies and drug stores	61.0%
All Other Segments Combined Share	39.0%

Source: Future Market Insights analysis of the nicotine gums and mints market, 2026.

What are the key drivers, restraints and opportunities?

Driver

Smokers who want to quit. Over 60% of smokers in countries covered by the Global Adult Tobacco Survey intend to quit. WHO states that counselling and medication can more than double a tobacco user's chance of quitting successfully. That intent supports demand across smoking cessation products.

Brand and store brand competition. Nicorette outperformed its category across major markets in the second quarter of 2026. Store brand nicotine replacement products also kept gaining share in the third quarter.

Restraint

Tighter over-the-counter rules. India's Drugs Technical Advisory Board recommended in February 2026 that the sales-licence exemption cover only unflavoured 2 mg gum. In August 2026 it also recommended that no new nicotine formulation be approved, after applications for nicotine pouches. The government has not yet taken a final decision.

Competition from other nicotine products. FDA authorized the marketing of 20 ZYN nicotine pouches products in January 2025. In England, nicotine pouches featured in 3.1% of quit attempts in 2023 to 2024.

Opportunity

Wider licensing of established brands. Nicotinell is licensed to Hikma across the Middle East and North Africa from September 2026. Its owner reports a footprint in over 30 countries across Europe, Asia including Japan, and Latin America.

Behavioral support. CDC advises using nicotine gum as part of a program that includes coaching support. In England, websites and smartphone apps featured in 4.6% and 3.6% of quit attempts in 2023 to 2024.

Nicotine Gums and Mints Market by Country (2026 to 2036)

Table 6: Nicotine Gums and Mints Market Country Growth Forecast

Country	CAGR, 2026 to 2036
India	6.0%
United States	5.3%
Australia	4.2%
United Kingdom	3.4%

Source: Future Market Insights analysis of the nicotine gums and mints market, 2026.

India

India has a very large smoking and smokeless tobacco population. Entry 33 of Schedule K to the Drugs Rules, 1945 exempts nicotine gum and lozenges from the sales licence. The exemption covers products with up to 2 mg of nicotine. The advisory board's February 2026 recommendation would narrow that exemption. Strong demand and regulatory risk support a 6.0% CAGR for 2026 to 2036, the highest among the four profiled countries.

Pool size and a low price ceiling explain the lead. India's 2016 to 2017 survey, the latest round, recorded 99.5 million smokers and 199.4 million smokeless users. Bidis reach 7.7% of adults against 4.0% for cigarettes. A daily bidi smoker spends INR 284.1 a month against INR 1,192.5 for a cigarette smoker. Gum pricing therefore faces a lower ceiling than in markets built on cigarette smokers. Smokeless users are a second pool, with 33.2% of users and recent quitters making a quit attempt in the past year.

India differs from the other profiled countries on three points. Intent is high, since 55.4% of smokers are planning or thinking about quitting. Clinical prompting lags, because only 48.8% of smokers who visited a health provider were advised to quit. India also prohibits e-cigarettes under a 2019 law, so quitters have no vape route. If adopted, the amendment would keep only unflavoured 2 mg gum outside the licence requirement. Lozenges of 2 mg would need a sales licence.

United States

Nicorette is marketed in the United States by a licensee of the brand owner, not by the owner itself. Competition between brands and store brands supports a 5.3% CAGR for 2026 to 2036.

CDC reported 28.8 million adult smokers in 2022, and 53.3% of smokers and recent quitters tried to quit that year. About two thirds (67.7%) wanted to quit, but only 8.8% quit successfully. Adult smoking then fell from 11.6% in 2022 to 9.1% in the latest national survey release. Treatment use is thin, as 38.3% of quitters used counseling or medication and 18.4% used gum or lozenges. Gum and lozenges therefore reach about one in five quitters, close to the 19.6% using patches.

Access rules, not intent, set the pace. Only 20 state Medicaid programs offered full barrier-free cessation coverage in 2022. Treatment use among uninsured adults was 20.4%, against 38.3% across all who tried to quit. CDC also noted the discontinuation of the nicotine oral inhaler, which narrows the choice of nicotine forms. Menthol smokers try to quit more often (57.3% against 50.4%) yet use treatment less (35.2% against 41.5%). Substitution is a second constraint, since 6.7% of adults use e-cigarettes against 9.1% who smoke. Gum suppliers therefore depend on insurer coverage and retail access to turn quit attempts into sales.

Australia

Nicabate, the local brand in Australia, belongs to the Nicotinell portfolio that Dr. Reddy's bought from Haleon in 2024. Falling smoking rates support steady but modest growth of 4.2% a year for 2026 to 2036.

Retail volume, not subsidy, drives Australian gum sales. Subsidised supply was 7% of all nicotine replacement use in 2019, so most is bought over the counter. Gum was the most commonly sold over-the-counter format, with 194 million of 257.4 million units sold. Gum earned AUD 56 million of AUD 152 million in retail value, the same as patches. Patches made up 94% of subsidised nicotine replacement, although gum has been listed since February 2019.

The smoker pool is shrinking quickly. Daily smoking among adults fell to 5.8% in 2025, which means 500,000 fewer daily smokers than three years earlier. Among people aged 14 and over, daily smoking was 5.6%, down from 8.3% in 2022 to 2023. Past-year use of any nicotine product fell to 15.2%, and daily vaping has stabilised at 3.6%. Tobacco remains the leading cause of premature death in Australia, taking more than 24,000 lives each year. The government announced that from 24 July 2026 individuals can no longer import nicotine pouches, even with a prescription. That leaves licensed products, such as gum, as the lawful route for Australian quitters who want nicotine replacement.

United Kingdom

Adult smoking stood at 9.5% in England in 2025. Legislation raising the age of sale of tobacco takes effect progressively from 1 January 2027. People born in or after 2009 can then never be legally sold tobacco. A shrinking smoker base limits growth to 3.4% a year for 2026 to 2036, the lowest among the profiled countries.

Substitution, more than prevalence, caps UK growth. Vapes have been the most popular quit aid in England since 2013. Over-the-counter nicotine replacement averaged 24.5% of attempts across 2006 to 2024, against 17.3% in 2023 to 2024. Unaided attempts also limit the market, at 40.8% of attempts in 2023 to 2024.

Survey evidence for over-the-counter nicotine replacement is weaker than for the alternatives. Prescription nicotine replacement was associated with higher quit success (odds ratio 1.33, 95% confidence interval 1.12 to 1.58). Over-the-counter nicotine replacement was not (odds ratio 1.03, 95% confidence interval 0.93 to 1.15). The study is a cross-sectional survey of all over-the-counter forms, so it does not isolate gum. Among quitters who used nicotine replacement, 38.8% still used it at the survey date, against 84.8% for e-cigarettes. The Swap to Stop scheme added about 125,000 people using vapes to quit in its first year. Free vape starter kits therefore give retail gum a funded competitor for each English quit attempt.

Who are the notable companies in the Nicotine Gums and Mints Market?

Notable companies in the Nicotine Gums and Mints Market include Kenvue, Perrigo, Dr. Reddy's, Cipla and Rusan Pharma.

Brand rights by territory set who sells nicotine gum in each market. Kenvue owns Nicorette and markets it outside the United States, while Haleon markets it in the United States under license. Kimberly-Clark completed its acquisition of Kenvue on 2 November 2026 and plans approximately USD 2.1 billion of run-rate synergies. Nicorette outperformed its category across major markets in the second quarter of 2026.

Dr. Reddy's holds Nicotinell and related brands outside the United States. It bought them from Haleon on 30 September 2024 for an up-front GBP 458 million. The portfolio covers over 30 countries. It includes Nicabate in Australia, Thrive in Canada and Habitrol in New Zealand and Canada. In September 2026 it granted Hikma exclusive rights to register, market and distribute Nicotinell across the Middle East and North Africa.

Perrigo supplies store brand nicotine replacement products to retailers. Its third quarter 2026 results of 4 November 2026 cite continued share gains for those products. They also cite share gains across U.S. store brand over-the-counter products.

Cipla Health sells Nicotex gums, lozenges and patches in India. It launched the Nicotex Begin 12-week cessation app in May 2025. India's Drugs Technical Advisory Board recommended in February 2026 that only unflavoured 2 mg gum stay outside the sales-licence requirement. Distributors in India could face licensing requirements for other nicotine replacement products if the government adopts it.

Rusan Pharma sells 2baconil nicotine gum in 2 mg and 4 mg strengths. It competes with Cipla Health in the Indian market for nicotine replacement products.

Key Developments in the Nicotine Gums and Mints Market

• In November 2026, Kimberly-Clark Corporation completed its acquisition of Kenvue Inc. in a cash-and-stock transaction valued at approximately USD 48.7 billion. The combined company unites 10 billion-dollar brands including Nicorette and targets approximately USD 2.1 billion in run-rate synergies from cost savings and revenue growth [citation follows last bibliography number, e.g. 25].
• In September 2026, Hikma Pharmaceuticals International Limited and Dr. Reddy’s Laboratories SA entered into a multi-year exclusive licensing and distribution agreement for Nicotinell across the Middle East and North Africa. Through the agreement, Hikma has the right to register, market and distribute Nicotinell across the region, adding the brand to its consumer health portfolio [26].

Key Players in the Nicotine Gums and Mints Market

• Kenvue Inc. (Kimberly-Clark Corporation)
• Perrigo Company plc
• Dr. Reddy's Laboratories Ltd.
• Cipla Health Ltd.
• Rusan Pharma Ltd.

Nicotine Gums and Mints Market Report Scope

Table 7: Nicotine Gums and Mints Market Report Scope

Coverage field	Report scope
Market definition	Nicotine polacrilex chewing gums and nicotine mints and lozenges sold as nicotine replacement products for smoking cessation, valued at manufacturer selling prices. Nicotine patches, inhalers, sprays and nicotine pouches are excluded.
Product Type	Nicotine gum; Nicotine mints and lozenges
Strength	Below 3 mg; 3 mg and above
Flavor	Mint; Fruit; Original and classic; Others
Distribution Channel	Pharmacies and drug stores; Supermarkets and hypermarkets; Convenience stores; Online retail; Others
Regions and profiled countries	North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa. Profiled countries: India, United States, Australia, United Kingdom
Companies covered	Kenvue Inc. (Kimberly-Clark Corporation); Perrigo Company plc; Dr. Reddy's Laboratories Ltd.; Cipla Health Ltd.; Rusan Pharma Ltd.
Quantitative Units	USD million

Nicotine Gums and Mints Market by Segments

Nicotine Gums and Mints Market segmented by Product Type:

• Nicotine gum
• Nicotine mints and lozenges

Nicotine Gums and Mints Market segmented by Strength:

• Below 3 mg
• 3 mg and above

Nicotine Gums and Mints Market segmented by Flavor:

• Mint
• Fruit
• Original and classic
• Others

Nicotine Gums and Mints Market segmented by Distribution Channel:

• Pharmacies and drug stores
• Supermarkets and hypermarkets
• Convenience stores
• Online retail
• Others

Nicotine Gums and Mints Market by Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East
• Africa
• India
• United States
• Australia
• United Kingdom

Research Sources and Bibliography

• [1] World Health Organization. (2026, June 26). Tobacco and nicotine fact sheet. https://www.who.int/news-room/fact-sheets/detail/tobacco
• [2] The Times of India. (2026, April 15). Curbs on nicotine gums, lozenges may make quitting harder, say experts. https://timesofindia.indiatimes.com/india/experts-warn-proposed-nicotine-product-restrictions-could-hinder-smoking-cessation-efforts-in-india/articleshow/130274512.cms
• [3] Kimberly-Clark Corporation. (2026, November 2). Kimberly-Clark Completes Acquisition of Kenvue. https://www.investor.kimberly-clark.com/news-releases/news-release-details/kimberly-clark-completes-acquisition-kenvue-creating-preeminent
• [4] Kenvue Inc. (2026, August 6). Kenvue reports second quarter 2026 results. https://www.kenvue.com/media/kenvue-reports-second-quarter-2026-results
• [5] Dr. Reddy's Laboratories Ltd. (2024, September 30). Completion of acquisition of Nicotinell and related brands (Form 6-K, Exhibit 99.1). https://www.sec.gov/Archives/edgar/data/1135951/000157587224001038/drr0676_ex99-1.htm
• [6] Perrigo Company plc. (2026, November 4). Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations. https://investor.perrigo.com/2026-11-04-Perrigo-Reports-Third-Quarter-2026-Financial-Results-From-Continuing-Operations
• [7] Pharmabiz. (2026, September 24). DTAB asks govt not to approve new nicotine formulations henceforth. https://www.pharmabiz.com/NewsDetails.aspx?aid=190795&sid=1
• [8] Action on Smoking and Health (ASH). (2026, October). Smoking Facts at a Glance. https://ash.org.uk/resources/view/facts-at-a-glance
• [9] Centers for Disease Control and Prevention. (2024, July 25). Adult Smoking Cessation: United States, 2022. Morbidity and Mortality Weekly Report, 73(29). https://www.cdc.gov/mmwr/volumes/73/wr/mm7329a1.htm
• [10] National Center for Health Statistics, CDC. (2025 data release). FastStats: Cigarette Smoking and Electronic Cigarette Use. https://www.cdc.gov/nchs/fastats/smoking.htm
• [11] Jackson, S. E., Brown, J., Buss, V., & Shahab, L. (2025, January 17). Prevalence of Popular Smoking Cessation Aids in England and Associations With Quit Success. JAMA Network Open, 8(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC11742533/
• [12] Ministry of Health and Family Welfare, Government of India. (2016-17 survey). Global Adult Tobacco Survey GATS 2 India Fact Sheet. https://assets.tobaccofreekids.org/global/pdfs/en/GATS_India_2016-17_FactSheet.pdf
• [13] PRS Legislative Research. (2019). The Prohibition of Electronic Cigarettes Bill, 2019. https://prsindia.org/billtrack/the-prohibition-of-electronic-cigarettes-production-manufacture-import-export-transport-sale-distribution-storage-and-advertisement-bill-2019
• [14] Australian Government Department of Health, Pharmaceutical Benefits Scheme. (2019-20 data). Post-market Review of medicines for smoking cessation, ToR 2: Utilisation of PBS-listed medicines for smoking cessation. https://www.pbs.gov.au/reviews/post-market-smoking-cessation-files/final-smoking-cessation-report-tor2.PDF
• [15] Butler, M., Australian Government. (2026, July 17). Australia's smoking rates declining. https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/australias-smoking-rates-declining?language=en
• [16] King's College London. (2026, March 5). Government Swap to stop scheme sees approximately 125,000 more people using vapes to try and quit smoking cigarettes. https://www.kcl.ac.uk/news/government-swap-to-stop-scheme-sees-approximately-125000-more-people-using-vapes-to-try-and-quit-smoking-cigarettes
• [17] Kenvue Inc. (2023, May 3). Prospectus, Form 424B4. https://www.sec.gov/Archives/edgar/data/1944048/000162828023015837/kenvue424b4.htm
• [18] Kenvue Inc. (2026, February). Annual Report on Form 10-K for the fiscal year ended December 28, 2025. https://www.sec.gov/Archives/edgar/data/1944048/000194404826000030/kvue-20251228.htm
• [19] Centers for Disease Control and Prevention. (2024, October 4). How to Use Nicotine Gum. Tips From Former Smokers. https://www.cdc.gov/tobacco/campaign/tips/quit-smoking/quit-smoking-medications/how-to-use-quit-smoking-medicines/how-to-use-nicotine-gum.html
• [20] Cipla Health Ltd. Nicotex. https://www.ciplahealth.in/brand/nicotex
• [21] Ahmed, A. (2025, May 14). Cipla Health launches mobile application Nicotex Begin for smokers. The Hindu BusinessLine. https://www.thehindubusinessline.com/companies/cipla-health-launches-mobile-application-nicotex-begin-for-smokers/article69575796.ece
• [22] Rusan Pharma Ltd. 2baconil Gum 2mg and 4mg Nicotine Gum. https://www.rusanpharma.com/2baconil-gum.html
• [23] U.S. Food and Drug Administration. (2025, January 16). FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products after Extensive Scientific Review. https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-20-zyn-nicotine-pouch-products-after-extensive-scientific-review
• [24] Shams Al Yaoum. (2026, September 28). Hikma signs exclusive licensing and distribution agreement with Dr. Reddy's Laboratories for Nicotinell across MENA. https://shams-alyaoum.com/en/hikma-signs-exclusive-licensing-and-distribution-agreement-with-dr-reddys-laboratories-for-nicotinell-across-mena/
• [25] Kimberly-Clark Corporation. (2026). Kimberly-Clark Completes Acquisition of Kenvue, Creating the Preeminent Global Consumer Health and Wellness Leader [Press release via PR Newswire]. https://investor.kimberly-clark.com [official Form 8-K, November 2, 2026, cited by credenceresearch.com and panabee.com]
• [26] Hikma Pharmaceuticals / Dr. Reddy’s Laboratories. (2026, September 28). Hikma signs exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories for Nicotinell across MENA. https://www.zawya.com/en/press-release/companies-news/hikma-signs-exclusive-licensing-and-distribution-agreement-with-dr.-reddys-laboratories-for-nicotinell-across-mena-1363870